The univariate analysis revealed significant contributors to the overall survival of PRAD were M stage (P < 0.001), Gleason scores (P = 0.019), primary therapy (P = 0.007), PSA values (P = 0.001) and POLG2 mRNA expression (P = 0.002), respectively. Here, POLG2 is linked to prostate adenocarcinoma.